IOVA
Iovance Biotherapeutics Inc
11.00$
-0.1%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +127.2% | +62.7% | -9.6% | +209.5% | -28.3% | +123.0% | +1.2% | -14.6% | +17.5% | +16.7% | +0.3% | |
| – | +131.2% | +63.0% | -11.9% | +218.4% | -33.4% | +101.0% | -20.1% | -5.7% | -35.7% | +48.5% | -3.1% | |
| – | +130.9% | +60.5% | -12.7% | -43.5% | -83.0% | +382.0% | +16.2% | +196.2% | -50.4% | +0.7% | +41.0% | |
| – | +130.9% | +60.5% | -12.7% | +222.3% | -34.5% | +105.0% | -19.9% | -6.5% | -40.7% | +15.7% | -8.3% | |
| – | – | – | – | – | – | – | – | – | – | +45,820.5% | +18.9% | |
| – | – | – | – | – | – | – | – | – | – | +396.7% | +0.3% | |
| – | +9.4% | +41.6% | +3.2% | +9.5% | +218.2% | +593.1% | +70.6% | +76.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +23.2% | -1.1% | |
| – | -1.9% | +204.8% | +99.1% | +47.9% | +212.3% | +145.1% | +39.0% | +5.6% | +19.1% | +2.2% | +7.3% | |
| – | -1.9% | +204.8% | +99.1% | +45.6% | +171.5% | +40.4% | +62.6% | +2.6% | +20.6% | +10.9% | +13.1% | |
| – | – | – | – | – | – | -13.3% | -19.5% | +148.9% | -38.2% | +65.8% | -68.6% | |
| – | -23.2% | -9.9% | +42.8% | +122.3% | +468.3% | -13.2% | +102.6% | -2.8% | +24.5% | -16.9% | -19.4% | |
| – | – | – | – | – | – | – | – | +0.0% | +0.0% | +0.0% | – | |
| – | +132.0% | +60.5% | -12.8% | +220.4% | -35.9% | +119.6% | -5.3% | -19.6% | +17.0% | +21.5% | -1.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +77.7% | +24.4% | +18.0% | +49.1% | +27.8% | +11.2% | +10.9% | +3.8% | +47.6% | +23.3% | +23.3% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.